MICA and melanoma: CEACAM1-3S is associated with enhanced immunogenicity and contributes to improved OS of patients with advanced melanoma; in contrast, CEACAM1-4L promotes tumor progression by downregulating the cell surface expression of the NKG2D ligands MICA and ULBP [44].